Global CNS Therapeutics Market 2018-2022 - Product Image

Global CNS Therapeutics Market 2018-2022

  • ID: 4564474
  • Report
  • Region: Global
  • 104 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Eli Lilly
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novartis
  • MORE
About CNS therapeutics

CNS therapeutics cater to CNS disorders that affect the structure or function of the brain or spinal cord such as Parkinson’s disease, epilepsy, Alzheimer’s disease, anxiety, depression, and bipolar disorders.

The analysts forecast the Global CNS therapeutics market to grow at a CAGR of 4.36% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the CNS therapeutics market. To calculate the market size, the report considers the revenue generated from the sales of therapeutics for CNS disorders.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global CNS Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novartis
Market drivers
  • Increasing prevalence of mental illness
  • For a full, detailed list, view the full report
Market challenges
  • Side effects of CNS therapeutics
  • For a full, detailed list, view the full report
Market trends
  • Increased adoption of new-generation drugs
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eli Lilly
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novartis
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: CUSTOMER LANDSCAPE

PART 08: MARKET SEGMENTATION BY END-USER
  • Segmentation by end-user
  • Comparison by end-user
  • MHDs - Market size and forecast 2017-2022
  • NDDs - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by end-user
PART 09: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Increasing awareness programs
  • Increased adoption of new-generation drugs
  • Advances in technology in treating mental disorders
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novartis
PART 15: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global healthcare market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global - Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Customer landscape
Exhibit 19: End-user - Market share 2017-2022 (%)
Exhibit 20: Comparison by end-user
Exhibit 21: MHDs - Market size and forecast 2017-2022 ($ mn)
Exhibit 22: MHDs - Year-over-year growth 2018-2022 (%)
Exhibit 23: NDDs - Market size and forecast 2017-2022 ($ mn)
Exhibit 24: NDDs - Year-over-year growth 2018-2022 (%)
Exhibit 25: Others - Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Others - Year-over-year growth 2018-2022 (%)
Exhibit 27: Market opportunity by end-user
Exhibit 28: Global - Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 32: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 33: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 34: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 35: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Rise in population aged 65 and above (% of total)
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Eli Lilly: Overview
Exhibit 45: Eli Lilly: Business segments
Exhibit 46: Eli Lilly: Organizational developments
Exhibit 47: Eli Lilly: Geographic focus
Exhibit 48: Eli Lilly- Segment focus
Exhibit 49: Eli Lilly: Key offerings
Exhibit 50: F. Hoffmann-La Roche overview
Exhibit 51: F. Hoffmann-La Roche- Business segments
Exhibit 52: F. Hoffmann-La Roche - Organizational developments
Exhibit 53: F. Hoffmann-La Roche- Geographic focus
Exhibit 54: F. Hoffmann-La Roche- Segment focus
Exhibit 55: F. Hoffmann-La Roche - Key offerings
Exhibit 56: Johnson & Johnson overview
Exhibit 57: Johnson & Johnson- Business segments
Exhibit 58: Johnson & Johnson- Organizational developments
Exhibit 59: Johnson & Johnson- Geographic focus
Exhibit 60: Johnson & Johnson- Segment focus
Exhibit 61: Johnson & Johnson- Key offerings
Exhibit 62: Merck: Overview
Exhibit 63: Merck: Business segments
Exhibit 64: Merck: Organizational developments
Exhibit 65: Merck: Geographic focus
Exhibit 66: Merck - Segment focus
Exhibit 67: Merck-Key offerings
Exhibit 68: Novartis: Overview
Exhibit 69: Novartis: Business segments
Exhibit 70: Novartis: Organizational developments
Exhibit 71: Novartis: Geographic focus
Exhibit 72: Novartis - Segment focus
Exhibit 73: Novartis-Key offerings
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Eli Lilly
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novartis
  • MORE
New Report Released: - Global CNS Therapeutics Market 2018-2022.

The author of the report recognizes the following companies as the key players in the CNS therapeutics market: Eli Lilly, F. Hoffmann-La Roche, Johnson & Johnson, Merck, Novartis.

Commenting on the report, an analyst from the research team said: “The increased adoption of new-generation drugs will be a key trend for the market growth. First-generation and second-generation drugs have many side-effects, limited therapeutic range, and complicated pharmacokinetics. Third-generation drugs have longer therapeutic ranges and limited side effects in comparison to the second-generation drugs, driving the adoption of third-generation drugs.”

According to the report, the increasing prevalence of mental illness will drive the market growth. Mental disorders coexist with diseases such as diabetes, cardiovascular disease, or obesity. The increased disease burden and mental disorders requires the availability of effective therapeutics for mental health to decrease the number of deaths caused due to mental illness.

Further, the report states that the side effects of CNS therapeutics will impact the market growth. Therapeutics for CNS disorders have numerous risks and side-effects such as drowsiness and weight gain, insomnia, lowered libido, tremors, and agitation. Also, anti-epilepsy medications result in periodic mood swings that are consequent in depression and anxiety.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novartis
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll